Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Other solid neoplasm 2CNS 2Tumor-Agnostic 1Plasma cell 1Other 1Genitourinary 1

Conditions

Chemotherapy-Induced Peripheral Neuropathy 1

Interventions

Exercise 28Metformin 24Surveys and Questionnaires 19Radiotherapy 14Methods 14Early Intervention, Educational 13Counseling 13Educational Status 12naloxegol 10Standard of Care 10Tirzepatide 9Nutrition Assessment 9Diet Therapy 9Cisplatin 9Resistance Training 8Psychiatric Rehabilitation 8Diet 8Therapeutics 7Interviews as Topic 7alvimopan 6Liraglutide 6Fibroblast Growth Factor 7 6Caloric Restriction 6semaglutide 5Radiation 5Low-Level Light Therapy 5Injections 5Exenatide 5Diet, Mediterranean 5Dexamethasone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cannabidiol × Other × Clear all
NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡